Table 2.

Univariate and multivariate analysis for overall survival.

Univariate analysis
Risk factor	HR	95.0% CI	P-value
Age ≥60 years	1.02	1.00–1.03	0.001
Liver metastases	1.70	1.28–2.24	<0.0001
LDH > 618 IU/L (ULN)	2.27	1.6–3.05	<0.0001
Albumin <3.5 g/dL (LLN)	2.00	1.33–2.99	0.001
KRAS mutations	2.10	1.47–3.02	<0.0001
TP53 mutations	1.61	1.22–2.13	0.001
CDKN2A mutations	1.68	1.12–2.52	0.01
P53 pathway abnormalities	1.79	1.32–2.42	<0.0001
PDGF signaling pathway abnormalities	1.35	1.00–1.83	0.049
Apoptosis signaling pathway abnormalities	1.61	1.21–2.14	0.001
Ras pathway abnormalities	1.83	1.37–2.44	<0.0001
T-cell activation pathway abnormalities	1.42	1.02–1.97	0.04
Multivariate analysis, OS
LDH > ULN (618 IU/L)	2.19	1.61–2.97	<0.0001
KRAS mutations	2.27	1.57–3.28	<0.0001
Albumin < LLN (3.5 g/dL)	1.90	1.26–2.87	0.002
Age ≥60 years	1.02	1.00–1.03	0.009
Liver metastases	1.43	1.07–1.91	0.02
TP53 mutations	1.38	1.04–1.84	0.025

Abbreviations: LDH lactate dehydrogenase, LLN lower limit of normal, OS overall survival, ULN upper limit of normal.